Revisión de stock de pulmatrix
With iSPERSE ™ technology, PULMATRiX is expanding therapeutic care for patients with serious disease through a new generation of View Pulmatrix, Inc. PULM investment & stock information. Get the latest Pulmatrix, Inc. PULM detailed stock quotes, stock data, Real-Time ECN, charts, stats Find the latest quotes for (Pulmatrix, Inc. Common Stock) (PULM) as well as charts and news at Nasdaq.com. Pulmatrix, Inc. Common Stock (PULM) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. 5 Aug 2019 Q2 2019 Highlights Pulmatrix achieved several clinical and business The increase was primarily due to increased stock compensation
2/21/2019 · Find the latest Pulmatrix, Inc. (PULM) stock quote, history, news and other vital information to help you with your stock trading and investing.
Barchart Opinion & Trading Performance. Barchart Opinions add market-timing information by calculating and interpreting signal strength and direction. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. PULM stock quote, chart and news. Get Pulmatrix, Inc.'s stock price today. Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including What's going on at Pulmatrix (NASDAQ:PULM)? View breaking news headlines for PULM stock from trusted media outlets at MarketBeat. 6/17/2019 · Pulmatrix, Inc. Common Stock (PULM) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including During the day the stock fluctuated 4.82% from a day low at $0.83 to a day high of $0.87. Quick summary: 30 day high of the PULM stock price was $0.90 and low was $0.80. 90 day high was $0.90 and low was $0.61. 52 week high for Pulmatrix - $3.01 and low - $0.10.
Descarga ahora la foto Revisión De Planos. Encontre más imágenes de alta resolución en la colección de iStock, que tiene un banco de fotos de 20 a 29 años
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily PULMATRiX, Inc. 99 Hayden Avenue | Suite 390 Lexington, MA 02421. Phone: 781-357-2333. Parking: Visitor parking is directly adjacent to our building; park either in the visitors' section next to the entrance or in the multi-level garage overlooking the visitors' spaces. Pulmatrix Stock Price Forecast, PULM stock price prediction. The best long-term & short-term Pulmatrix share price prognosis for 2019, 2020, 2021, 2022, 2023, 2024 pulmatrix stock to take or not to take? Stock like roulette – today green, tomorrow red. You can seriously increase your capital after a while or, conversely, after a while your capital may decline. Terms of investing in pulmatrix stock. When investing in a tool like stocks, you need to focus on a long term: a few years or a few dozen years. 1/17/2017 · Pulmatrix shares reacted to the news, skyrocketing nearly 138% to $1.62 in Tuesday’s trading session. “The new QIDP designation is a significant boost to our efforts to make this drug available as quickly as possible to cystic fibrosis (CF) patients suffering from fungal lung infections,” said Pulmatrix CEO Robert Clarke, PhD. PULM: Get the latest Pulmatrix stock price and detailed information including PULM news, historical charts and realtime prices. Get breaking news and analysis on Pulmatrix, Inc. (PULM) stock, price quote and chart, trading and investing tools.
Pulmatrix Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. Pulmatrix, Inc. Common Stock, also called Pulmatrix, is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. Read More The firm focuses on the prevention and treatment of respiratory diseases and infections. Barchart Opinion & Trading Performance. Barchart Opinions add market-timing information by calculating and interpreting signal strength and direction. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.
View Pulmatrix, Inc. PULM investment & stock information. Get the latest Pulmatrix, Inc. PULM detailed stock quotes, stock data, Real-Time ECN, charts, stats
6/17/2019 · Pulmatrix, Inc. Common Stock (PULM) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including During the day the stock fluctuated 4.82% from a day low at $0.83 to a day high of $0.87. Quick summary: 30 day high of the PULM stock price was $0.90 and low was $0.80. 90 day high was $0.90 and low was $0.61. 52 week high for Pulmatrix - $3.01 and low - $0.10.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. Pulmatrix, Inc. Common Stock, also called Pulmatrix, is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. Read More The firm focuses on the prevention and treatment of respiratory diseases and infections. Barchart Opinion & Trading Performance. Barchart Opinions add market-timing information by calculating and interpreting signal strength and direction. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. PULM stock quote, chart and news. Get Pulmatrix, Inc.'s stock price today. Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including What's going on at Pulmatrix (NASDAQ:PULM)? View breaking news headlines for PULM stock from trusted media outlets at MarketBeat. 6/17/2019 · Pulmatrix, Inc. Common Stock (PULM) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.